Award Number: DAMD17-01-1-0236

TITLE: Evaluation of Feasibility for a Case-Control Study of Pituitary-Ovarian Function in Premenopausal Women with Breast Cancer

PRINCIPAL INVESTIGATOR: Joanne F. Dorgan, Ph.D.

CONTRACTING ORGANIZATION: Fox Chase Cancer Center
Philadelphia, Pennsylvania 19111

REPORT DATE: July 2004

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
Evaluation of Feasibility for a Case-Control Study of Pituitary-Ovarian Function in Premenopausal Women with Breast Cancer

Joanne F. Dorgan, Ph.D.

Fox Chase Cancer Center
Philadelphia, Pennsylvania 19111

E-Mail: Joanne.Dorgan@fcc.edu

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

20041028 139

Approved for Public Release; Distribution Unlimited

Background: Postmenopausal women with elevated estrogens are at an increased risk of breast cancer, but an association of estrogens with breast cancer in premenopausal women has not been clearly established.

Objective/Hypothesis: We will evaluate the feasibility of a case-control study that uses gonadotropin releasing hormone (GnRH) agonist stimulation tests to compare pituitary-ovarian function in premenopausal women with breast cancer with unaffected controls. Hypotheses to be tested in the full-scale study are: 1) premenopausal women with breast cancer secrete more luteinizing hormone (LH) and follicle stimulating hormone (FSH) in response to GnRH compared to controls; 2) premenopausal women with breast cancer secrete more estradiol and testosterone in response to gonadotropins, and this is related to their higher insulin like growth factor -1 (IGF-1) levels compared to controls; 3) increased estradiol production in premenopausal women with breast cancer is due to increased enzyme activity at a specific step in steroidogenesis. Specific Aims: Specific aims of the feasibility study are: 1) determine the feasibility of a full-scale study; 2) gather preliminary data on basal and GnRH stimulated serum levels of LH, FSH, estradiol, and testosterone in women with breast cancer compared to controls. Study Design: A case-control study will be conducted at FCCC.

GnRH

Unclassified

Unclassified

Unclassified

Unlimited
Table of Contents

Front Cover ................................................................. 1
Standard Form 298 ......................................................... 2
Table of Contents .......................................................... 3
Introduction .................................................................... 4
Body ............................................................................. 4
Key Research Accomplishments ........................................ 5
Reportable Outcomes ..................................................... 6
Conclusions ..................................................................... 6
References ....................................................................... 6

Appendices ..................................................................... 6
Introduction: Elevated serum estrogen levels in postmenopausal women have been shown to increase the risk of breast cancer. However, the association of serum estrogens with breast cancer in premenopausal women has not been established. The purpose of this study is to determine the safety and feasibility of conducting a case-control study that uses gonadotropin releasing hormone (GnHR) stimulation tests to evaluate the sensitivity of the hypothalamic pituitary ovarian (H-P-O) axis in premenopausal women with breast cancer compared to unaffected premenopausal women. The full-scale study will determine if: 1) the anterior pituitary of pre-menopausal women with breast cancer secretes more luteinizing hormone (LH) and follicle stimulating hormone (FSH) in response to GnRH compared to controls; 2) the ovaries of pre-menopausal women with breast cancer secrete more estradiol and testosterone in response to gonadotropins, and this is related to their higher insulin like growth factor –1 (IGF-1) levels compared to controls; 3) increased estradiol production by the ovaries in premenopausal women with breast cancer is due to increased enzyme activity at a specific step in steroidogenesis.

Body: Research accomplishments are described for each task outlined in the approved statement of work.

Task 1: Prepare for data collection, Months 1-2

a. Finalize data collection protocol and forms. This activity has been completed and all questionnaires have been approved by both the FCCC IRB and the DOD IRB.
b. Finalize database design and data entry screen. This activity has been completed.
c. Hire and train program coordinator. This activity has been completed.

Task 2. Identify and recruit participants, Months 2-6

a. Search the FCCC Tumor Registry and Health Information Management System (HIMS) to identify potential cases and benign breast disease controls. The FCCC IRB required that we conduct the study in phases – recruiting and conducting GnRH stimulation tests in healthy premenopausal women during the first phase and conducting GnRH stimulation tests in premenopausal women treated for stage 0 or stage 1 breast cancer who did not receive any chemotherapy and who completed adjuvant therapy at least one year earlier during the second phase. Twenty one women who may be potentially eligible for Phase 2 have been identified by using HIMS.
b. Obtain physician approval to contact cases and benign breast disease controls. Physicians have approved a letter drafted to contact their patients who may be eligible for Phase 2. They have not been contacted regarding specific cases because we are awaiting DOD approval of the letter. FCCC IRB had approved this letter in January 2004.
c. Identify one friend control who is eligible and agrees to participate for each case. Friend controls have been replaced with healthy community controls because of the IRB’s concerns about asking cases to identify friends who did not have breast cancer. This was approved in the original protocol submitted to the DOD.
d. Send approximately 50 letters. Letters have been sent to 53 women.
e. **Perform approximately 50 telephone interviews.** As of May 12, 2004, 97 interested, premenopausal women have called in to obtain more information about the study. Twenty-two women were not eligible for participation based on the preliminary screening questionnaire approved by the FCCC and DOD IRBs. Twenty-five women were no longer interested once they received more information about the study. Thirty-nine women were potentially eligible based on the screening interview completed over the phone. An additional 41 women were interested after recruitment for healthy women ceased.

**Task 3. Conduct data collection visits, Months 3-8.** We have received FCCC IRB and DOD IRB approval of changes to the protocol submitted in June 2003 before beginning data collection visits.

a. **Administer 27 questionnaires.** Ten questionnaires have been administered.

b. **Measure heights and weights of 27 participants.** Heights and weights have been measured for 10 participants.

c. **Perform 27 GnRH stimulation tests, collect and store serum specimens.** Ten GnRH stimulation tests have been performed. These serum specimens were collected and are currently stored in the FCCC Biosample Repository.

d. **Isolate DNA from lymphocytes for 27 participants and store.** DNA has been isolated for 10 participants and are currently stored in the FCCC Biosample Repository.

e. **Key and verify data.** Data has been keyed and verified for 10 participants.

**Task 4. Create a serum pool for laboratory quality control, Month 8.** This task will be done when we get closer to conducting laboratory analyses.

**Task 5. Measure LH, FSH, estradiol, testosterone, IGF-1, and IGFBP-3 concentrations in serum from 27 participants, Months 9-10.** This task will be done after the GnRH stimulation study. Estradiol has been measured in 10 samples. All results were found to be within normal range. Based on these results the FCC Data and Safety Monitoring Board and the DOD IRB approved continuing to Phase 2 of the study, which involves testing women with a history of stage 0 or 1 breast cancer.

**Task 6. Analyze data and write reports, Months 11-12.** This task will be completed in the future.

a. Perform statistical analyses

b. Write final report

c. Begin writing grant proposal for full scale study

**Key Research Accomplishments:**

- Our goal for the first phase of the study is to recruit 10 women.
- Ten women have completed Phase I of the study.
- After Phase I was completed, the study received the approval to continue with Phase II from the FCCC Data Safety Monitoring Board and the DOD IRB.
- Twenty-one women have been identified for Phase II of the study.
**Reportable Outcomes:** None at this time.

**Conclusions:** This is an interim report for a pilot study. Based on our experience to date, it appears that we will be able to recruit healthy controls for a full scale case-control study that uses gonadotropin releasing hormone (GnRH) stimulation to determine sensitivity of the hypothalamic pituitary ovarian (H-P-O) axis in premenopausal women with breast cancer compared to unaffected premenopausal women. The full-scale study will also evaluate whether differences in serum IGF-1 and IGFBP-3 contribute to observed differences in ovarian steroidogenesis in premenopausal women with breast cancer and controls. Furthermore, it will determine if increased production of estrogens in premenopausal women with breast cancer following GnRH stimulation is related to increased enzyme activity at a specific step in the steroidogenesis pathway. Identification of the hormonal cause for breast cancer in premenopausal women could ultimately lead to detection of populations at increased risk, approaches to screening for women at high risk, and/or chemopreventive strategies that target the responsible enzyme or regulatory protein.

**References:** None at this time.

**Appendices:** None at this time.